Anti-Involucrin [SY8]
Exclusive toolSY8 is useful for studies of changes in involucrin expression in pathological studies.
Contributors
| Inventor | Institute |
|---|---|
| Fiona Watt | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| SKU: | 151164 |
|---|---|
| Product description: | SY8 is useful for studies of changes in involucrin expression in pathological studies. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Molecular weight: | 66-170 kDa |
| Immunogen: | Purified involucrin from human keratinocytes. |
| Myeloma used: | P3X63Ag8 |
| Cat. #: | 151164 |
|---|---|
| Provenance and Ownership: | The Anti-Involucrin [SY8] is owned by Cancer Research UK. CancerTools supplies the Anti-Involucrin [SY8] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Involucrin [SY8] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer; Cell signaling and signal transduction |
| Application: | IHC ; IF ; IP ; WB |
| Target: | Involucrin |
| Reactivity: | Dog ; Human ; Pig ; Primate |
| Clone: | SY8 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Involucrin is a protein precursor of the epidermal cornified envelope and a differentiation marker of human keratinocytes. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Howie et al. 2011. PLoS Pathog. 7(8):e1002211. PMID: 21901101. Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. Hudson et al. 1992. Hybridoma. 11(3):367-79. PMID: 1500072. Characterisation of eight monoclonal antibodies to involucrin. |
|---|
Images
View Gallery
Product Images
b73cbed6-01b4-48b1-8ab4-ed769ddccaee.jpg
Adapted from Howie et al. 2011. PLoS Pathog. 7(8)
